Cardiology
RSSArticles
-
Full November 2004 Issue in PDF
-
Pharmacology Watch: The FDA and Merck Fielding Concerns About Vioxx
Merck announced on September 30th that it is voluntarily withdrawing rofecoxib (Vioxx) from the worldwide market. -
Painless Aortic Dissection
Patients with painless acute aortic dissection are more likely to present with syncope, congestive heart failure or stroke, and have a higher mortality, especially with type B dissection. -
Antibiotics and Sudden Cardiac Death
Patients who use both erythromycin and CYP3A inhibitors, particularly calcium channel blockers, had an increased risk of sudden death from cardiac causes. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Update: Acamprosate Calcium Tablets (Campral®)
The FDA has approved a new drug for the management of alcohol dependence. -
Resolution of Hepatitis C Infection
Studies on HCV infection resolution show that PBMC HCV-RNA may remain, despite clearance of the virus from plasma. -
Sayonara, Sinus Headaches
Headaches commonly attributed to sinus are very likely to be migraines. -
Full October 15, 2004, Issue in PDF
-
Pharmacology Watch: Linking COX-2 Inhibitors and Cardiovascular Event Risk
A new and as yet unpublished study has raised increased concern about the relationship between rofecoxib (Vioxx), Mercks blockbuster COX-2 inhibitor, and cardiovascular events.